{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T02:16:02Z","timestamp":1791857762804,"version":"4.3.4"},"reference-count":20,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T00:00:00Z","timestamp":1773187200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Advanced hepatocellular carcinoma (HCC) and unresectable liver metastases present significant therapeutic challenges, particularly in patients with portal vein tumor thrombus or complex vascular architecture. This study evaluates the safety and feasibility of a novel layered embolization strategy combining drug-eluting and uniform-caliber microspheres.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      We conducted a prospective, single-arm clinical trial enrolling 33 patients with advanced HCC (BCLC stage C) or unresectable liver metastases and preserved liver function (Child-Pugh class A\/B \u22647). The layered strategy involved initial embolization with 100-300 \u03bcm CalliSpheres\n                      <jats:sup>\u00ae<\/jats:sup>\n                      drug-eluting microspheres loaded with epirubicin, followed by proximal flow blockade with 100\/500\/700 \u03bcm uniform-caliber blank microspheres. Primary endpoints were safety profiles and procedural feasibility; secondary endpoints included short-term imaging response and biomarker dynamics.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The procedure was technically successful in all patients. Treatment-related adverse events occurred in 28 patients (84.8%), with 96.4% being grade 1\u20132 according to CTCAE v5.0 criteria. The most common complications were hepatic function abnormalities (72.7%) and post-embolization syndrome (60.6%). All adverse events resolved with standard management within a median of 7 days. Among 27 evaluable patients, the disease control rate was 92.6% (7 partial responses, 18 stable disease, 2 progression). Tumor biomarker dynamics showed correlation with imaging response.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This layered embolization strategy demonstrates an acceptable safety profile and technical feasibility in carefully selected patients with advanced liver tumors and preserved hepatic function. The findings provide a foundation for future randomized controlled trials to evaluate survival benefits and identify optimal patient subgroups.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fonc.2026.1773259","type":"journal-article","created":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T05:37:14Z","timestamp":1773207434000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Safety and feasibility of a layered embolization strategy with drug-eluting and uniform-caliber microspheres for advanced hepatocellular carcinoma and unresectable liver metastases: a prospective single-arm clinical trial"],"prefix":"10.3389","volume":"16","author":[{"given":"Xiangrui","family":"Chen","sequence":"first","affiliation":[{"name":"Department of Oncology, Zigong Third People\u2019s Hospital","place":["Zigong, Sichuan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louzong","family":"Sun","sequence":"additional","affiliation":[{"name":"Department of Hepatobiliary Surgery, Zigong First People\u2019s Hospital","place":["Zigong, Sichuan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Hu","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Zigong Third People\u2019s Hospital","place":["Zigong, Sichuan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ju","family":"Zhou","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Zigong Third People\u2019s Hospital","place":["Zigong, Sichuan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chengluo","family":"Hao","sequence":"additional","affiliation":[{"name":"Department of Oncology, Zigong Third People\u2019s Hospital","place":["Zigong, Sichuan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunwei","family":"Han","sequence":"additional","affiliation":[{"name":"Department of Oncology, Affiliated Traditional Chinese Medicine Hospital of Southwest Medical University","place":["Luzhou, Sichuan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,3,11]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3350\/cmh.2024.0824","article-title":"Hepatocellular carcinoma: updates on epidemiology, surveillance, diagnosis and treatment","volume":"31","author":"Hwang","year":"2025","journal-title":"Clin Mol Hepatol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-023-00825-3","article-title":"Global trends in hepatocellular carcinoma epidemiology: implications for screening, prevention and therapy","volume":"20","author":"Singal","year":"2023","journal-title":"Nat Rev Clin Oncol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1002\/hep.28431","article-title":"Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes","volume":"64","author":"Younossi","year":"2016","journal-title":"Hepatol (Baltimore Md)"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1001\/jamasurg.2022.7989","article-title":"Management of hepatocellular carcinoma: A review","volume":"158","author":"Brown","year":"2023","journal-title":"JAMA Surg"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.21037\/hbsn-22-469","article-title":"A review of 2022 Chinese clinical guidelines on the management of hepatocellular carcinoma: updates and insights","volume":"12","author":"Xie","year":"2023","journal-title":"Hepatobil Surg Nutr"},{"key":"B6","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.ctrv.2018.11.002","article-title":"Updated use of TACE for hepatocellular carcinoma treatment: How and when to use it based on clinical evidence","volume":"72","author":"Raoul","year":"2019","journal-title":"Cancer Treat Rev"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD009498.pub4","article-title":"Transarterial (chemo)embolisation versus no intervention or placebo for liver metastases","volume":"3","author":"Swierz","year":"2020","journal-title":"Cochrane Database Syst Rev"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1097\/js9.0000000000001819","article-title":"Lenvatinib plus drug-eluting bead transarterial chemoembolization with\/without hepatic arterial infusion chemotherapy for hepatocellular carcinoma larger than 7 cm with major portal vein tumor thrombosis: a multicenter retrospective cohort study","volume":"110","author":"Cai","year":"2024","journal-title":"Int J Surg (London England)"},{"key":"B9","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1038\/s41392-024-02012-x","article-title":"Comparison of drug-eluting bead transarterial chemoembolization combined with apatinib versus drug-eluting bead transarterial chemoembolization for the treatment of unresectable hepatocellular carcinoma: a randomized, prospective, multicenter phase III trial","volume":"9","author":"Duan","year":"2024","journal-title":"Signal Transduct Target Ther"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2016.01.012","article-title":"Sorafenib or placebo plus TACE with doxorubicin-eluting beads for intermediate stage HCC: The SPACE trial","volume":"64","author":"Lencioni","year":"2016","journal-title":"J Hepatol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.3727\/096504018x15313896322888","article-title":"Efficacy and safety of CalliSpheres(\u00ae) drug-eluting beads transarterial chemoembolization in Barcelona clinic liver cancer stage C patients","volume":"27","author":"Liu","year":"2019","journal-title":"Oncol Res"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1007\/s12094-018-1902-8","article-title":"CalliSpheres\u00ae drug-eluting beads (DEB) transarterial chemoembolization (TACE) is equally efficient and safe in liver cancer patients with different times of previous conventional TACE treatments: a result from CTILC study","volume":"21","author":"Zhang","year":"2019","journal-title":"Clin Trans Oncol Off Publ Fed Spanish Oncol Societies Natl Cancer Institute Mexico"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.4103\/jcrt.jcrt_218_23","article-title":"Evaluation of the efficacy and safety of CalliSpheres\u00ae microsphere-transarterial chemoembolization in large hepatocellular carcinoma","volume":"19","author":"Zhou","year":"2023","journal-title":"J Cancer Res Ther"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.3760\/cma.j.cn112137-20230630-01114","article-title":"Chinese clinical practice guidelines for transarterial chemoembolization of hepatocellular carcinoma (2023 edition)","volume":"103","year":"2023","journal-title":"Zhonghua yi xue za zhi"},{"key":"B15","doi-asserted-by":"publisher","first-page":"3166","DOI":"10.3390\/cancers15123166","article-title":"Outcomes of transarterial embolisation (TAE) vs. Transarterial chemoembolisation (TACE) for hepatocellular carcinoma: A systematic review and meta-analysis","volume":"15","author":"Lawson","year":"2023","journal-title":"Cancers"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1007\/s00270-016-1426-y","article-title":"Unresectable hepatocellular carcinoma: radioembolization versus chemoembolization: A systematic review and meta-analysis","volume":"39","author":"Lobo","year":"2016","journal-title":"Cardiovasc Intervent Radiol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2024.1511210","article-title":"Transarterial radioembolization versus chemoembolization for hepatocellular carcinoma: a meta-analysis","volume":"14","author":"Lu","year":"2024","journal-title":"Front Oncol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.15075","article-title":"Transarterial chemoembolization (TACE) combined with sorafenib versus TACE for hepatocellular carcinoma with portal vein tumor thrombus: a systematic review and meta-analysis","volume":"8","author":"Zhang","year":"2017","journal-title":"Oncotarget"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1080\/17843286.2022.2076791","article-title":"Hepatic arterial infusion chemotherapy versus transarterial chemoembolization for patients with unresectable hepatocellular carcinoma: a systematic review and meta-analysis","volume":"78","author":"Kong","year":"2023","journal-title":"Acta Clin Belgica"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.576232","article-title":"Treatment response, survival, and safety of transarterial chemoembolization with CalliSpheres(\u00ae) microspheres versus conventional transarterial chemoembolization in hepatocellular carcinoma: A meta-analysis","volume":"11","author":"Liang","year":"2021","journal-title":"Front Oncol"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1773259\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T05:37:15Z","timestamp":1773207435000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1773259\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,11]]},"references-count":20,"alternative-id":["10.3389\/fonc.2026.1773259"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1773259","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,11]]},"article-number":"1773259"}}